Ulrike Poetschger
Overview
Explore the profile of Ulrike Poetschger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
415
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pichler H, Sedlacek P, Meisel R, Beier R, Faraci M, Kalwak K, et al.
Br J Haematol
. 2024 May;
205(1):268-279.
PMID: 38803040
This prospective multicentre trial evaluated the safety and the efficacy of a thiotepa/melphalan-based reduced intensity conditioning (RIC) haematopoietic stem cell transplantation (HSCT) in children and adolescents with chronic myeloid leukaemia...
2.
Flaadt T, Ladenstein R, Ebinger M, Lode H, Arnardottir H, Poetschger U, et al.
J Clin Oncol
. 2023 Feb;
41(17):3135-3148.
PMID: 36854071
Purpose: Patients with relapsed high-risk neuroblastoma (rHR-NB) have a poor prognosis. We hypothesized that graft-versus-neuroblastoma effects could be elicited by transplantation of haploidentical stem cells (haplo-SCT) exploiting cytotoxic functions of...
3.
Eichinger A, Poetschger U, Glogova E, Bader P, Basu O, Beier R, et al.
Leukemia
. 2022 Sep;
36(11):2567-2576.
PMID: 36097283
Total body irradiation (TBI)-based conditioning is associated with superior leukemia-free survival in children with ALL undergoing HSCT. However, the risk for subsequent malignant neoplasms (SMN) remains a significant concern. We...
4.
Zubarovskaya N, Bauer D, Ronceray L, Poetschger U, Kurzmann P, Lender C, et al.
Front Pediatr
. 2022 May;
10:862455.
PMID: 35498780
[This corrects the article DOI: 10.3389/fped.2021.798974.].
5.
Wieczorek A, Manzitti C, Garaventa A, Gray J, Papadakis V, Valteau-Couanet D, et al.
Cancers (Basel)
. 2022 Apr;
14(8).
PMID: 35454826
Neurotoxicity is an off-tumour, on-target side effect of GD2-directed immunotherapy with monoclonal antibodies. Here, we report the frequency, management and outcome of patients enrolled in two prospective clinical trials who...
6.
Zubarovskaya N, Bauer D, Ronceray L, Poetschger U, Kurzmann P, Lender C, et al.
Front Pediatr
. 2022 Feb;
9:798974.
PMID: 35127596
Thyroid disorders are well-studied after allogeneic haematopoietic stem cell transplantation (HSCT) following total body irradiation (TBI)-based conditioning, occurring in 15-30% of paediatric survivors. The toxic effect of TBI is known...
7.
Garaventa A, Poetschger U, Valteau-Couanet D, Luksch R, Castel V, Elliott M, et al.
J Clin Oncol
. 2021 Jun;
39(23):2552-2563.
PMID: 34152804
Purpose: Induction therapy is a critical component of the therapy of high-risk neuroblastoma. We aimed to assess if the Memorial Sloan Kettering Cancer Center (MSKCC) N5 induction regimen (MSKCC-N5) would...
8.
Peters C, Dalle J, Locatelli F, Poetschger U, Sedlacek P, Buechner J, et al.
J Clin Oncol
. 2020 Dec;
39(4):295-307.
PMID: 33332189
Purpose: Total body irradiation (TBI) before allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients with acute lymphoblastic leukemia (ALL) is efficacious, but long-term side effects are concerning. We investigated...
9.
Dalle J, Balduzzi A, Bader P, Pieczonka A, Yaniv I, Lankester A, et al.
Bone Marrow Transplant
. 2020 Aug;
56(1):257-266.
PMID: 32753706
Allogeneic HSCT represents the only potentially curative treatment for very high risk (VHR) ALL. Two consecutive international prospective studies, ALL-SCT-(I)BFM 2003 and 2007 were conducted in 1150 pediatric patients. 569...
10.
Balduzzi A, Dalle J, Wachowiak J, Yaniv I, Yesilipek A, Sedlacek P, et al.
Biol Blood Marrow Transplant
. 2019 Jul;
25(11):2197-2210.
PMID: 31319153
Eligibility criteria for hematopoietic stem cell transplantation (HSCT) in acute lymphoblastic leukemia (ALL) vary according to disease characteristics, response to treatment, and type of available donor. As the risk profile...